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GENOME-WIDE INTERACTION ANALYSIS BETWEEN MITOCHONDRIAL SNPs AND
NUCLEAR SNPs ON OSTEOPOROSIS
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Osteoporosis is a typical complex disease of reduced bone mineral density (BMD).
Previous studies demonstrated that mitochondrial single nucleotide polymor-
phisms (mtSNPs) and nuclear SNPs (nSNPs) are involved in the pathogenesis.
However, possible mtSNP-nSNP interactions of most non-significant SNPs were
usually ignored and led to missing heritability. In this study, we performed a
genome-wide association study (GWAS) to explore potential mtSNP-nSNP interac-
tions contributing to osteoporosis susceptibility in a sample of 2,286 Caucasian
subjects. Correlation analysis was carried out for 44 mtSNPs and 562,011 nSNPs on
spine and hip BMD. Eventually, we found interactions involving 5 mtSNPs and 26
nSNPs that correlated with BMD (Without interaction analysis, these SNPs did not
show any significant correlation with BMD). Four pairs of the most significant
interaction SNPs with BMD were: mtSNP ND5-rs3135030 and nSNP RORB-rs950058 (P
Z 8.051014, spine BMD), mtSNP Cytb-rs28357375 and nSNP TOMM20-rs4920161
(P Z 1.281012, spine BMD), mtSNP Cytb-rs28357375 and nSNP VRK2-rs2678919
(P Z 2.611013, spine BMD), mtSNP Cytb-rs28573847 and nSNP CAMTA1-
rs873433 (P Z 3.851012, hip BMD). Besides, there were three newly reported
genes: ZNF518B, RMST, and APPADC1A, with more than one significant nSNPs.
These results provide new insights into the pathogenesis of osteoporosis.
http://dx.doi.org/10.1016/j.jot.2016.06.05933
ATTENUATION OF COLLAGEN-INDUCED ARTHRITIS BY POTENTIAL ANTI-
INFLAMMATORY DRUG GENISTEIN IN DBA/1 MICE
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Background: This work aimed to evaluate the effects of genistein treatment CIA in
mice. The CIA model was used to observe the treatment effects of genistein.
Methods: After the onset of arthritis, animals were divided into two groups accord-
ing to their clinical symptom scores. The treatment group was intraperitoneally
injected daily with genistein (based on the pre-experiment data and literature re-
ported, 5 mg/kg dose was selected and tested) for 12 days, whereas phosphate
buffered saline was used for the control group. Cytokine titre, radiological, and
histological examinations were performed at different time points after treat-
ment. CT analysis was conducted three months after the treatment to observe
the articular structures. Immunohistochemical analysis was performed to investi-
gate the expression and distribution of VEGF in joint tissues.
Results: Genistein reduced the secretions of IL-1b, IL-6 and TNF-a in the serum.
Radiological results showed that bone degradation was inhibited by the treatment.
Moreover, haematoxylin and eosin staining showed that the degree of inflamma-
tion was significantly alleviated. TRAP stain-positive cells were also detected in
the destruction of the articular cartilage, which was significantly reduced in the
treatment group compared with the control group. Micro-CT 3D images clearly
exhibited that the joint adhesions and structures were destroyed in the control
group. Furthermore, genistein suppressed VEGF expression and blocked angiogen-
esis in the synovial tissue.Conclusion: This study provides further evidence regarding the effects of genistein
as a potential treatment drug for RA, as well as the role of genistein in the anti-
inflammatory pathway in RA therapy.
http://dx.doi.org/10.1016/j.jot.2016.06.06036
CXCR1 KNOCKDOWN IMPROVES THE SENSITIVITY OF OSTEOSARCOMA TO
CISPLATIN
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Introduction: Chemoresistance is one major cause of the poor prognosis of
osteosarcoma. Cisplatin is one of the basic drugs of osteosarcoma chemotherapy,
but many patients showed resistance to cisplatin in osteosarcoma treatment.
Objectives: The aim of this study is to investigate if CXCR1 knockdown could
improve the cisplatin sensitivity of osteosarcoma and the depth of molecular
mechanisms.
Methods: 1. Comparison of the cisplatin sensitivity of the highly metastatic
Saos2-lung osteosarcoma cells and its parental Saos2 cells: Two osteosarcoma
cell lines, including the Saos2 and Saos2-lung, which is a highly metastatic oste-
osarcoma cell line derived from Saos2, were treated with cisplatin and their
sensitivity to cisplatin was compared by a CCK-8 test and an apoptosis assay.
The expression of CXCR1 was detected by Western Blot. 2. Sensitivity of osteo-
sarcoma cells to cisplatin treatment and the molecular mechanisms after CXCR1
knockdown: Saos2 and Saos2-lung cells were transfected with two shRNA against
CXCR1 sequences by lentivirus. The chemotherapy sensitivity to the cisplatin
with or without the stimulation of IL-8 was determined and western blot was
used to test the activation of the Akt signalling pathway. 3. Cisplatin sensitivity
of Saos2-lung cells after CXCR1 knockdown in vivo: The Saos2-lung with lucif-
erase labelling with CXCR1 knockdown or control cells were injected into the
bone marrow cavity of the tibia of nude mice with cisplatin treatment. The
tumour size and the luciferase intensity of nude mice bearing tumours were
detected. The expression of IL8, CXCR1, p-Akt, PCNA, and Cleaved-Caspase-3
were also determined by immunohistochemistry.
Results: 1. Comparison of the cisplatin sensitivity of the highly metastatic Saos2-
lung osteosarcoma cells and its parental Saos2 cells: The cisplatin chemotherapy
sensitivity of Saos2 cells is stronger than Saos2-lung cells, which have higher
expression of CXCR1. 2. Sensitivity of osteosarcoma cells to cisplatin treatment
and the molecular mechanisms after CXCR1 knockdown: CXCR1 knockdown cell
line of Saos2 and Saos2-lung cells has been established, respectively. CXCR1 knock-
down improved the cell’s sensitivity to the cisplatin greatly and IL-8 could reduce
the chemotherapy sensitivity of osteosarcoma cells, which could be blocked by
CXCR1 knockdown. Western Blot showed that CXCR1 knockdown suppressed the
Akt signal pathway, which was activated by IL-8. 3. Cisplatin sensitivity of Saos2-
lung cells after CXCR1 knockdown in vivo: Compared with the control group, the
tumour size was reduced greatly, which was consistent with the luciferase inten-
sity. The expression of IL8, CXCR1, p-Akt, and PCNA were suppressed and
Cleaved-Caspase-3 was increased in CXCR1 knockdown groups under the treatment
of cisplatin.
Conclusions: Knockdown of CXCR1 in osteosarcoma cells could improve its
chemotherapy sensitivity to cisplatin, which may be regulated partly by the IL-
8/CXCR1/Akt signalling pathway. CXCR1 will be a new target for osteosarcoma
treatment.
http://dx.doi.org/10.1016/j.jot.2016.06.061
